-
-
-
-
-
-
-
Larimar Therapeutics, Inc. (LRMR) Misses Q3 EPS by 20c
-
-
-
-
-
-
-
Larimar Therapeutics (LRMR) Provides Nomlabofusp Development Update
-
-
-
-
-
-
-
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
-
-
-
-
-
-
-
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial
-
-
-
-
-
-
-
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
-
-
-
-
-
-
-
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
1,219,016 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

